Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.53 |
| ▸ | GAA | P10253 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KDM6B | O15054 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.42 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.42 |
| ▸ | HMBS | P08397 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513216 | 0.83 | SPR (0.56) | SPRKDM4EGAAHSD17B10HPGD | |
| SCHEMBL5791701 | 0.81 | SPR (0.54) | SPRKDM4EGAAHSD17B10HPGD | |
| Hydrochloric Acid SCHEMBL5010691 | 0.79 | SPR (0.53) | SPRKDM4EGAAHSD17B10HPGD | |
| SCHEMBL4734537 | 0.78 | KDM4E (0.68) | SPRKDM4EGAAHSD17B10HPGD | |
| SCHEMBL17770626 | 0.76 | KDM4E (0.55) | KDM4EGAAHSD17B10HPGDALDH1A1 | |
| SCHEMBL11120767 | 0.75 | SPR (0.49) | SPRKDM4EGAAHSD17B10HPGD | |
| SCHEMBL8121938 | 0.75 | ALDH1A1 (0.60) | SPRKDM4EGAAALDH1A1GLA | |
| SCHEMBL4230546 | 0.74 | KDM4E (0.53) | KDM4EGAAHSD17B10HPGDALDH1A1 | |
| SCHEMBL31547664 | 0.74 | KDM4E (0.53) | KDM4EGAAHSD17B10HPGDALDH1A1 | |
| SCHEMBL17503590 | 0.74 | KDM4E (0.53) | KDM4EGAAHSD17B10HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| US-20240374583-A1 | USE OF MORPHINAN DERIVATIVES FOR TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASE | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-11-14 | — | — | US | disclosed |
| US-12109209-B2 | Use of morphinan derivatives for treatment of opioid delta receptor agonist-related disease | NIPPON CHEMIPHAR CO., LTD. (JP) | 2024-10-08 | — | — | US | disclosed |
| EP-4414037-A2 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASES | Nippon Chemiphar Co., Ltd. (JP) | 2024-08-14 | — | — | EP | disclosed |
| WO-2024158878-A1 | FUSED TETRACYCLIC SELECTIVE PARP1 INHIBITORS | ENLIVEN INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| EP-3513792-B9 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASES | NIPPON CHEMIPHAR CO (JP) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024134514-A1 | NOVEL COMPOUND AS RON INHIBITOR | 주식회사 엘지화학 | 2024-06-27 | — | — | WO | disclosed |
| CN-113292559-B | Morphinan derivatives | 日本化学药品株式会社 | 2024-04-02 | — | — | CN | disclosed |
| EP-3513792-B1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASES | NIPPON CHEMIPHAR CO (JP) | 2024-03-27 | — | — | EP | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| US-5312922-A | Quinoline derivatives with hydroxy, trifluoromethyl, carboxy and/or bromo substituents | NORDION INTERNATIONAL INC. (CA) | 1994-05-17 | — | — | US | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
| EP-0190265-B1 | PYRIDONE ESTERS AS INOTROPIC AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-01-08 | — | — | EP | disclosed |
| EP-0190265-A4 | PYRIDONE ESTERS AS INOTROPIC AGENTS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1987-07-09 | — | — | EP | disclosed |
| US-4657919-A | CARDIOVASCULAR DISORDERS | E. I. DU PONT DE NEMOURS & CO. (US) | 1987-04-14 | — | — | US | disclosed |
| EP-0190265-A1 | PYRIDONE ESTERS AS INOTROPIC AGENTS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1986-08-13 | — | — | EP | disclosed |
| WO-1986001202-A1 | PYRIDONE ESTERS AS INOTROPIC AGENTS | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1986-02-27 | — | — | WO | disclosed |
| US-4559347-A | 3-Substituted-5-alkyl-1,6-naphthyridin-2(1H)-ones, cardiotonic use and preparation thereof | STERLING DRUG INC. (US) | 1985-12-17 | — | — | US | disclosed |
| US-4555517-A | Pyridone esters as inotropic agents | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1985-11-26 | — | — | US | disclosed |
| US-3965107-A | Isothiazolopyridinones | ROHM AND HAAS COMPANY (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | SPR 2629/4885KDM4E 2656/4885GAA 1962/4885 |
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | ZC3HAV1, IL5, TYMP | SPR 3931/4885KDM4E 508/4885GAA 1363/4885 |
| US-20240374583-A1 | USE OF MORPHINAN DERIVATIVES FOR TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASE | OPRD1, OPRM1, OPRK1 | SPR 2233/4885KDM4E 4829/4885GAA 1826/4885 |
| US-12109209-B2 | Use of morphinan derivatives for treatment of opioid delta receptor agonist-related disease | OPRD1, OPRM1, OPRK1 | SPR 2233/4885KDM4E 4829/4885GAA 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.